Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Moderate to Severe Chronic Hand Eczema
NCT03861455Phase 2Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Jul 2019
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic hand eczema (CHE) comparing Dupilumab Group with Placebo Group (2 arms). Primary endpoint: modified Total Lesion Symptom Score at 16 weeks. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
chronic hand eczema (CHE)
Beyond the preview
Go deeper on NCT03861455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03861455.